rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AEON
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket
      Nov 17BenzingaAYTUAEON
      Aeon Biopharma amends warrant terms, expects $6.2 million in proceeds
      Nov 3Investing.comAEON
      AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar
      Oct 5Yahoo FinanceAEON
      Lake Street Remains a Buy on AEON Biopharma (AEON)

      Detailed price information for Aeon Biopharma Inc (AEON-A) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailAEON
      12 Health Care Stocks Moving In Thursday's After-Market Session
      Sep 10BenzingaAEON
      12 Health Care Stocks Moving In Thursday's Intraday Session
      Sep 10BenzingaTNONAEON
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Sep 10BenzingaTNONAEON
      12 Health Care Stocks Moving In Wednesday's After-Market Session
      Sep 9BenzingaEXOZAEON
      Laidlaw initiates Aeon Biopharma stock coverage with buy rating
      Sep 9Investing.comAEON
      AEON Biopharma names Paul Lee as acting chief regulatory officer
      Aug 24Investing.comAEON
      AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

      - Former Deputy Director of the FDA’s Office of Neuroscience  - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate...

      Aug 24BarchartAEON
      Aeon Biopharma director Timothy Lynch buys $243,455 in stock
      Aug 22Investing.comAEON

      This is the newest page. Registered accounts read further back.